|
EORTC AISBL / IVZW |
|
|
EORTC AISBL / IVZW |
Open studies are marked with a purple background, closed studies have a grey background, studies to be opened have a white background
| 06971 | A Phase III Study of PSC-833 in Combination with Vincristine, Doxorubicin and Dexamethasone (PSC-833/VAD) versus VAD Alone in Patients with Relapsing and Refractory Multiple Myeloma |
| 06964 | Phase II study of the efficacy of rH Inteleukin-2 in patients with slowly progressing acute myelogenous leukemia (AML) and with limited bone marrow blastosis after autologous stem cell transplantation or chemotherapy. |
| 06954 | Randomized phase III study to evaluate the value of rHuG-CSF in induction and of an oral schedule as consolidation treatment in elderly patients with acute myelogenous leukemia (AML-13 protocol) (Jointly with the GIMEMA) |
| 06950 | Pilot study for therapy of Philadelphia positive adult acute lymphoblastic leukaemia (Jointly with the Groupe Fran‡ais d'Etude de la LAL and GIMEMA, Italy) |
| 06952 | Induction with All-Trans Retinoic Acid in combination with Idarubicin followed by intensive consolidation followed by bone marrow transplantation or a randomized maintenance treatment depending upon the amount of minimal residual disease in collaboration with GIMEMA-AIEOP Cooperative Groups) |
| 06921 | A pilot phase II study of an intensified remission induction chemotherapy followed by an autologous or allogeneic bone marrow transplantation for bad prognosis myelodysplastic syndromes (MDS) and acute myelogenous leukemia secondary (sAML) to MDS of more than six months duration in patients with age younger than 60 years |
| 06923 | Randomized phase III study testing the effect of bone marrow transplantation or conventional chemotherapy with or without alpha Interferon for aggressive myeloma |
| 06911 | Pilot study for the evaluation of rhGM-CSF before induction chemotherapy in hairy cell leukemia |
| 06915 | A randomized phase III trial of all transRetinoic Acid followed by conventional chemotherapy versus conventional chemotherapy alone in acute promyelocytic leukemia. |
| 06914 | Phase II-III study of VAD (Vincristine, Doxorubicin, Dexamethasone) versus VAD plus Cyclosporin in patients with progressive multiple myeloma |
| 06913 | Pilot Study of VAD (vincristine, doxorubicin, dexamethasone) combined with cyclosporin in patients with progressive multiple myeloma. |
| 06903 | A randomized phase III multicenter trial comparing LD-ARA-C alone versus LD-ARA-C + GM-CSF versus LD-ARA-C + recombinant interleukin-3 for patients with myelodysplastic syndromes and a high risk of developing acute leukemia |
| 06893 | A phase II randomized study of 5-aza-2'-deoxycytidine with M-AMSA or with idarubicine in patients with relapsed acute leukemia |
| 06902 | A pilot multicenter study of recombinant human interleukin-3 (IL-3) plus LD-ARA-C in patients with myelodysplastic syndromes and a risk of developing acute leukemia |
| 06892 | A randomized phase III study on the value of GM-CSF administration as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myelogenous leukemia |
| 06888 | A pilot (phase II) study of intensive remission induction chemotherapy for bad prognosis myelodysplastic syndromes (MDS) and acute myelogenous leukemia secondary (sAML) tp MDS of more than 6 months duration in patients with age younger than 60 years |
| 06885 | A randomized phase I - II dose-finding study of human GM-CSF in patients with MDS at relatively low risk of developing acute leukemia |
| 06886 | Randomized phase II study with GM-CSF and low-dose ARA-C in patients with "high risk" myelodysplastic syndromes |
| 06872 | Phase II study of the effect of tumor necrosis factor (TNF-alpha) in refractory or relapsed acute non-lymphoblastic leukemia |
| 06862 | A controlled phase III study on the value of intensive remission induction and remission maintenance chemotherapy in elderly patients with acute myelogenous leukemia (AML-9) |
| 06852 | Phase II protocol for the evaluation of pentostatin (2'deoxycoformycin, NSC 21832) in therapy of refractory lymphoid neoplasms |
| 06851 | Phase II trial of recombinant alpha-2 interferon in patients with myelodysplastic syndromes |
| 06842 | Phase II trial of human alpha-2 recombinant interferon for chronic myeloid leukemia in the chronic phase |
| 06843 | Phase II trial for the treatment of lymphoblastic transformation of chronic myeloid leukemia (LBT-CML) |
| 06993 | Gemtuzumab Ozogamicin (CMA-676) followed or not by intensive chemotherapy as initial treatment for elderly patients with acute myeloid leukemia: an EORTC-LG pilot phase II study. |
| 06951 | A randomized phase III trial comparing Dexamethasone with Prednisone in induction treatment and bone marrow transplantation followed by low maintenance vs intensive maintenance treatment in adolescent and adult acute lymphoblastic leukemia (ALL-4) (in collaboration with LALA) |
| 06861 | Phase III trial for adolescent and adult "high" risk acute lymphoblastic leukemia (AA-ALL) and lymphoblastic lymphoma (LL) |
| 06863 | A randomized phase III study of autologous bone marrow transplantation versus intensive consolidation during first complete remission in acute myelogenous leukemia (AML-8A) |
| 06864 | A randomized phase III study of intensive consolidation with high dose cytosine arabinoside in acute myelogenous leukemia (AML-8B) |
| 06961 | A randomized phase III study for autologous peripheral blood stem cell transplantation (PSCT) vs a second intensive consolidation course after a common induction and consolidation course in patients with bad prognosis MDS and sAML to MDS of more than 6 months duration. |
| 06931 | Randomized phase III study of induction (ICE vs MICE vs DCE) and intensive consolidation (IDIA vs NOVIA vs DDIA) followed by allogeneic bone marrow transplantation or a randomized autologous BMT vs autologous peripheral stem cell transplantation in acute myelogenous leukemia |
| 06975 | A phase II Multicenter study of Amifostine in patients with myelodysplastic dyndromes at relatively low risk of developing acute leukemia |
| 06891 | A randomized phase I/II multicenter study of recombinant human interleukin-3 (IL-3) in patients with myelodysplastic syndromes at relatively low risk of developing acute leukemia. |
| 06013 | Idarubicin and Ara-C in combination with Gemtuzumab-Ozogamycin (IAGO) for untreated patients, with or without an HLA identical sibling, with high risk MDS or AML developing after a preceding period with MDS during 6 months duration : a phase II study. |
| 06023 | Randomized phase II trial with infliximab (Remicade (R)) in patients with myelodysplastic syndrome and a relatively low risk of developing acute leukemia. |
| 06012 | Gemtuzumab Ozogamycin (GO) combined with standard intensive chemotherapy versus standard intensive chemotherapy alone for induction/consolidation in patients 61 - 75 years old with previously untreated AML : a randomized phase III trial (AML-17) of the EORTC - LG and the GIMEMA-ALWP |
| 06011 | Intravenous low-dose decitabine versus supportive care in elderly patients with primary Myelodysplastic Syndrome (MDS) (>10% blasts or high-risk cytogenetics), secondary MDS or Chronic Myelomonocytic Leukemia (CMML) who are not eligible for intensive therapy: an EORTC-German MDS Study Group randomized phase III study. |
| 06992 | Trial 06992: Low dose Chlorambucil maintenance vs. no treatment following high-dose Chlorambucil induction in patients with advanced B-Chronic Lymphocytic Leukemia. A Randomized phase III study of the EORTC LG (CLL-3). |
| 06991 | The value of high dose versus standard dose Ara-c during induction and IL-2 after intensive consolidation/autologous stem cell transplantation in patients (age 15-60 yrs) with acute myelogenous leukemia. A randomized phase III trial of the EORTC and GIMEMA Leukemia Cooperative Groups (AML-12). |
| 06956 | Treatment of relapsed Acute Myelogenous Leukemia consisting of intermediate dose Cytosine Arabinoside (Ara-C) plus interspaced continuous infusion Idarubicine, followed by continous infusion of low dose Ara-C, a Phase II study |
| 06962 | A randomized phase III study to assess intensification of the conditioning regimen for allogenic and autologous stem cell transplantation for myeloid and lymphoid malignancies with a high risk of relapse. |
| 06941 | A feasibility study for the therapy of chronic myeloid leukemia with recombinant Interferon Alpha plus All-Trans Retinoic Acid (ATRA) |
| 06942 | A randomized phase III trial of 2-Chloro-Deoxyadenosine vs Fludarabine in patients with pretreated B-chronic lymphocytic leukemia |
| 06916 | A randomized phase II trial of high-dose Chlorambucil versus Fludarabine in patients with advanced B-chronic lymphocytic leukemia |
| 06887 | Randomized phase III study comparing hydroxyurea with Interferon alpha-2C in the chronic phase of chronic myeloid leukemia |
| 06083 | Clofarabine added to prephase and consolidation therapy in acute lymphoblastic leukemia in adults. A prospective randomized trial. |
| 06071 | A phase III randomized, Double-blind study of induction (Daunorubicin/Cytarabine) and consolidation (high-dose Cytarabine) chemotherapy + Midostaurin (PKC 412) (IND # TBD) or Placebo in newly diagnosed patients <60 years of age with FLT3 mutated acute myeloid leukemia (AML) |
| 06061 | Clofarabine in combination with a standard remissioninduction regimen (AraC and idarubicin) in patients 18-60 years old with previously untreated intermediate and bad risk acute myelogenous leukemia (AML) or high risk myelodysplasia (MDS) : a phase I-II study of the EORTC-LG and GIMEMA (AML-14A trial) |
| 06031 | Gemtuzumab ozogamicin (GO) monotherapy versus standard supportive care for previously untreated AML in elderly patients who are not eligible for intensive chemotherapy : a randomized phase II/III trial (AML-19) of the EORTC-LG and GIMEMA-ALWP. |
| 06901 | A phase II study on salvage treatment for primary resistant acute myelogenous leukemia consisting of intermediate doses cytosine arabinoside and interspaced continuous infusions of idarubicin |